Gsk Share Discussion Threads

[whatsup32] 27/5/2021 16:22

Thanks Euro. Wasn’t clear why GSK came back 10p . That explains it.

Thinking of buying in next week

[markbelluk] 27/5/2021 16:18

Over 16,000,000 volume in BUYS in the post market auction. That caused the UT to be 1340 and the jump from -1.8% to 0.98% close

[eurofox] 27/5/2021 16:09

shows a lot of sellers of GSK below 1340 were all mopped up

[eurofox] 27/5/2021 16:08

The uncrossing prices set the closing prices and these were GSK = 1340, AV. = 412.5 and RR. = 107.06

[whatsup32] 27/5/2021 16:04

Eurofox. Not sure I have right closing price can you or anyone else give closing for
GSK, Av. , RR.

Thanks

[eurofox] 27/5/2021 15:37

thanks to the sellers, topped up at 1330

[spoole5] 27/5/2021 15:23

Here comes sub 13 quid.

[williamcooper104] 27/5/2021 14:47

Cheers - will have a look at those

[williamcooper104] 27/5/2021 14:46

Elliot's analysis will be something like 1 buy in and wait for existing management to deliver on plans - with sufficient kicking to make sure this happens - turn £11-13 into £18 - 1.5x unlevered over say 3 years worst case with 2x cheap margin/equity swap leverage should hit their 20 plus IRR targets 2 buy in and manage to break the whole thing up then get to maybe £25 2 would have been the absolute home run but they'll be happy with 1, and they will have been very aware of the political risks in pulling 2 off Just because they are activists doesn't mean they have to be capital A activists on each position

[porsche1945] 27/5/2021 14:17

2williamcooper

Yeah yeah yeah I’m sue the Times has the inside track on Elliot’ intentions.....not. You really think they have spent billions to sit about waiting for the cxxp management to get their sxxt together?

Two good tips, buy enphase and palantir, 4x ers over next couple of years, plus usd protection. Buy them.

[spoole5] 27/5/2021 12:13

Back sub13 soon. Maybe that will concentrate a few institutional investor minds

[daneswooddynamo] 27/5/2021 11:46

Certainly doesn’t seem to fit the description of multi-billion given 3 percent around 2 billion. Just journo hyperbole to make a headline

[geckotheglorious] 27/5/2021 10:17

Still no mention of the size of the Elliott stake as far as I can see...

So it can't be as big as Times is intimating.

[xxxxxy] 27/5/2021 09:47

GlaxoSmithKline (GSK.L) has launched a new trial for a COVID-19 vaccine, while an existing antibody treatment has received an emergency use authorisation from the US.The pharmaceutical giant, which has been looking to bring a new coronavirus vaccine to the market by the end of the year, announced on Thursday that it has initiated a global phase three clinical efficacy study.The vaccine could be approved in the fourth quarter of 2021 pending positive outcomes and regulatory reviews, the company said. Manufacturing will begin in the coming week to enable rapid access to the vaccine should it be approved.The company, which is lagging behind its rivals in the fight against coronavirus, has partnered with French firm Sanofi.The new trial follows the interim phase two results which showed that their vaccine candidate achieved high rates of neutralising antibody responses in all adult age groups, with 95% to 100% seroconversion rates.After a single injection, high neutralising antibody levels were also generated in participants with evidence of prior infection, which suggests strong potential for development as a booster vaccine, GSK said.?GSK shares were flat on Thursday. Chart: Yahoo FinanceMore"We believe further solutions for COVID-19 are very much needed to help reach people around the world, especially as the pandemic evolves and variants continue to emerge," said Roger Connor, president of GSK vaccines."Adjusting our technology and study designs reflects this need and will further build the potential of this adjuvanted protein-based vaccine. We are grateful to the volunteers who will take part in the trials and hope the results will add to the encouraging data we've seen so far so we can make the vaccine available as quickly as possible."The GSK vaccine was originally expected to receive regulatory approval in the first half of this year, however, it was delayed in December as it failed to produce a strong immune response in older people.The UK had pre-ordered around 60 million doses of the GSK-Sanofi vaccine as of December.Read more: COVID vaccine boosts UK investor confidence but Brexit fears still lingerThe news came as an antibody treatment called sotrovimab received an emergency green light from the US Food and Drug Administration (FDA) to treat mild-to-moderate COVID-19 in people 12 years of age and older.GSK revealed that treatment with sotrovimab resulted in an 85% reduction in the risk of hospitalisation or death in high-risk adult outpatients compared to placebo, based on interim results from Phase 3 COMET-ICE trial.It will be available for patients diagnosed with COVID-19 in the US in the coming weeks, while discussions with global regulators in additional countries continue. The antibody drug is not authorised for patients who require oxygen therapy.Read more: Japan approves AstraZeneca COVID vaccine ahead of Tokyo OlympicsThe news comes as Emma Walmsley, GSK's chief executive, has been put under pressure after activist investor Elliott Management took a multibillion-pound stake in the company in April.The US hedge fund is known for having waged campaigns for change at a number of high-profile firms, including mining group BHP (BHP.L), and Premier Inn owner Whitbread (WTB.L).According to the Times on Thursday, Elliott Management will not push for a sale of GSK's vaccines and pharmaceuticals business. It is also understood that it is not planning to push for cuts to the company's £5bn ($7bn) research and development budget, and will be supportive of GSK remaining in the UK..... Yahoo Finance

[spoole5] 27/5/2021 09:25

Elliott: change is comingElliott: no change is coming!

[alex1621] 27/5/2021 09:15

I never bought on account of Elliot, as they came in later. The positive is that they will keep the Board and CEO on their toes, and that's not a bad thing.

[montyhedge] 27/5/2021 08:00

Always said sweet FA Elliott can do.

[spud] 27/5/2021 07:57

Sanofi, GSK Covid-19 Vaccine Begins Major Trials, Aiming for Approval by Year EndSource: Dow Jones NewsBy Pietro Lombardi Sanofi SA and GlaxoSmithKline PLC are starting large-scale human trials of their Covid-19 vaccine candidate, which will involve more than 35,000 people, and said the vaccine could be approved by the end of the year.French Sanofi and U.K.-based GSK said Thursday that the phase 3 study will use two formulations; one will target the original strain, while the other will target the so-called South African variant."The design of the Phase 3, conducted across a broad diversity of geographies, also allows evaluation of the efficacy of the candidate against a variety of circulating variants," the companies said.The vaccine candidate may be approved in the last quarter of the year, depending on the outcome of the study and regulatory reviews. Production will start in coming weeks, so that the vaccine will be quickly accessible if it is approved.A booster study will also start in coming weeks, to evaluate the vaccine's ability to generate a strong booster response regardless of initial vaccine platform received.spud

[daneswooddynamo] 27/5/2021 07:47

Elliott’s calls to other shareholders have fallen on deaf ears, at least at this stage

[tradermichael] 27/5/2021 07:41

The very act of purchasing at that level was enough to push the share price up. Job done?

[spud] 27/5/2021 07:33

So Elliot just want to negate EW?spud

[spoole5] 27/5/2021 07:30

The share price isn't gonna move without the company being ripped apart and being sold to organisations that can run the individual parts better. If elliott are banking on that being gsk they will get bored and move on very quickly. Not usually their style

[abdullla] 27/5/2021 07:10

Not today Josephine!

[tradermichael] 27/5/2021 06:57

So, a massive investment in a company that 'must do better'? He obviously has confidence that he can make money on a recovering share price!

[williamcooper104] 27/5/2021 00:14

The Times reporting Elliott Management will not push for a sale of GlaxoSmithKline's vaccines and pharmaceuticals business, signalling that the US activist hedge fund is not seeking to wage an aggressive and politically contentious campaign against the British drugs group.It is also understood that Elliott is not planning to push for cuts to Glaxo's £5 billion research and development budget, and will be supportive of GSK remaining in the UK.https://www.thetimes.co.uk/article/elliott-we-won-t-force-glaxo-sale-hbkwv2jwj